Asiaticon Hand Sanitizer Recall: CGMP Failures Highlight International Sourcing Risks
Asiaticon, SA de CV's V-Klean Hand Sanitizer Gel Alcohol 70% faced a Class II recall (D-0116-2021) due to critical Current Good Manufacturing Practices (CGMPs) deficiencies at its Ciudad De Mexico facility. This voluntary recall, involving 111,500 units distributed in Texas, underscores the persistent regulatory risks associated with outsourced manufacturing of over-the-counter (OTC) products. Procurement and regulatory teams must intensify supplier qualification and oversight, particularly for international partners, to mitigate supply chain disruptions and ensure product quality.
FDA Action Details: Asiaticon's V-Klean Hand Sanitizer Recall Due to CGMP Deficiencies
The U.S. Food and Drug Administration (FDA) initiated a Class II recall (D-0116-2021) for V-Klean Hand Sanitizer Gel Alcohol 70%, manufactured by Asiaticon, SA de CV, citing a critical "Lack of Current Good Manufacturing Practices (CGMPs)." This voluntary, firm-initiated recall, announced via press release, involved 111,500 units of the product, distributed in Texas. The affected product was packaged in 8.5 fl oz (250 ml), 16.9 fl oz (500 ml), and 33.8 fl oz (1000 ml) bottles, all bearing the UPC 716053704993. The recall was initiated on August 25, 2020, and officially terminated on May 17, 2023, indicating the firm completed its corrective actions. For procurement directors, this event underscores the severe implications of CGMP non-compliance, which can range from inadequate raw material testing and poor process controls to insufficient facility sanitation and untrained personnel. Such failures directly compromise product quality, safety, and efficacy, leading to significant financial losses from product returns, destruction, and potential legal liabilities. Regulatory affairs heads must interpret "Lack of CGMPs" as a broad indicator of systemic quality control breakdowns, necessitating a thorough re-evaluation of any supplier's quality management system. Supply chain VPs should recognize that a Class II recall, where product use may cause temporary or medically reversible adverse health consequences, demands immediate and decisive action to protect consumers and brand reputation. Business development executives must factor in the heightened regulatory scrutiny on health-related products, even seemingly simple over-the-counter (OTC) items like hand sanitizers, when assessing market entry or partnership opportunities.
Manufacturer Profile: Asiaticon, SA de CV's Operational Footprint and Product Scope
Asiaticon, SA de CV, located at Conkal No. 62, Jardines del Ajusco, Tlalpan, Ciudad De Mexico, 14200, Mexico, was identified as the manufacturer of the recalled V-Klean Hand Sanitizer Gel Alcohol 70%. This facility's role in producing a high-volume consumer health product destined for the U.S. market highlights the complexities and risks inherent in international pharmaceutical and chemical supply chains. While specific details regarding the facility's capacity or broader product portfolio are not disclosed in the recall notice, the involvement of 111,500 units distributed in Texas suggests a substantial production capability and market reach for this particular product. For procurement directors, sourcing from international facilities, particularly in regions with diverse regulatory landscapes, introduces a critical layer of risk. The recall of a product like hand sanitizer, which gained significant demand during the pandemic, emphasizes the need for robust supplier qualification processes that extend beyond initial audits. Regulatory affairs teams must ensure that foreign suppliers, such as Asiaticon, adhere not only to local manufacturing standards but also meet the stringent Current Good Manufacturing Practices (CGMP) requirements mandated by the FDA for products imported into the United States. This often necessitates comprehensive on-site inspections, continuous monitoring of quality metrics, and clear contractual agreements outlining compliance expectations. Supply chain VPs must account for potential disruptions, including import alerts or bans, when engaging with international partners, making geographical diversification and contingency planning essential components of their strategy. Understanding the full operational footprint of a manufacturer, even with limited public data, is paramount for effective risk management.
Supply Chain Impact: Navigating the Ramifications of the V-Klean Recall in the US Market
The distribution pattern of Asiaticon, SA de CV's V-Klean Hand Sanitizer Gel Alcohol 70% was specifically identified as "Distributed in Texas," affecting a substantial quantity of 111,500 units across various packaging formats. This localized yet significant market penetration for a non-compliant product carries considerable ramifications for the entire supply chain, from distributors and retailers to healthcare providers and end-consumers within the state. The recall's Class II classification, indicating a potential for temporary or reversible adverse health consequences, amplified the urgency for rapid removal from the market and effective communication with stakeholders. For supply chain VPs, managing a recall of this magnitude requires immediate activation of reverse logistics protocols, precise inventory tracking, and coordination with regulatory bodies to ensure all affected units are identified and retrieved. The financial implications extend beyond the cost of product destruction to include potential penalties, lost sales, and the erosion of brand trust for any entities involved in its distribution. Procurement directors must assess the ripple effect on their own product lines if they relied on Asiaticon, SA de CV for similar components or finished goods, even if not directly involved in this specific recall. This incident highlights the critical need for robust traceability systems that can quickly pinpoint affected batches and limit the scope of a recall. Business development executives must consider the reputational damage associated with such recalls, not only for the manufacturer but also for any distributors or retailers who carried the product, potentially impacting future partnerships and market access. Proactive risk assessments and clear contractual obligations with distributors are vital to mitigate these widespread impacts.
Post-Recall Resolution and Future Regulatory Vigilance for Hand Sanitizer Products
The termination of the D-0116-2021 recall for Asiaticon, SA de CV's V-Klean Hand Sanitizer Gel Alcohol 70% on May 17, 2023, signifies that the company has, to the FDA's satisfaction, completed the necessary corrective actions and removed the non-compliant product from the market. While this closure provides a formal resolution to the immediate issue, it does not diminish the underlying compliance concerns raised by the "Lack of Current Good Manufacturing Practices (CGMPs)" observation. This event serves as a crucial case study for the global chemical and life sciences industry, particularly for companies engaged in the production or sourcing of over-the-counter (OTC) drug products. For regulatory affairs heads, the successful termination of a recall underscores the importance of a robust corrective and preventive action (CAPA) system and effective communication with regulatory agencies. However, it also reinforces that FDA scrutiny on internationally manufactured OTC products remains consistently high. Future sourcing decisions for hand sanitizers and similar health products must incorporate enhanced due diligence, focusing not just on a supplier's initial compliance but also on their demonstrated ability to maintain sustained adherence to CGMP standards post-recall. Procurement directors should consider this incident a significant flag in Asiaticon's regulatory history, necessitating more frequent and in-depth audits, potentially requiring additional quality agreements that specify performance metrics and remediation timelines. Supply chain VPs should implement continuous monitoring programs for all suppliers, especially those with past compliance issues, to proactively identify and mitigate risks before they escalate to another recall. This incident reinforces the importance of a proactive, rather than reactive, approach to regulatory intelligence and supplier management, ensuring long-term product quality and market access.